Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

Tumor Biology

Volumn 32, Issue 2, 2011, Pages 381-390

  Shi, Yan ^a   Chen, Li ^a   Li, Jie ^a   Lv, Ya Li ^a   Sun, Qiong ^a   Wang, Ling Xiong ^a   Jiao, Shun Chang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Immunohistochemistry; NSCLC; pAkt 1; pERK1 2; Recurrence free survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NAVELBINE; PACLITAXEL; PHOSPHORYLATED PROTEIN AKT 1; PROTEIN AKT 1; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; DEOXYCYTIDINE; DRUG DERIVATIVE; PROTEIN KINASE B; TAXOID; TUMOR MARKER; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADJUVANT CHEMOTHERAPY; CHINA; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHINA; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 79953806752     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0131-8     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. doi:10.3322/CA.2007.0010.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-60. (Pubitemid 38101630)
3. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-97. (Pubitemid 41007845)
4. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-27.
5. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22(19):3860-7. doi:10.1200/JCO.2004.01.153. (Pubitemid 41079866)
6. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127(3):978-83. doi:10.1378/chest.127.3.978. (Pubitemid 40775532)
7. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60(3):401-7. doi:10.1016/j.lungcan.2007.10.014. (Pubitemid 351726353)
8. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355 (10):983-91. (Pubitemid 44343542)
9. Breen D, Barlési F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(5):805-11. doi:10.1016/j.ejcts.2008.01.067.
10. Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13(3):994-9. (Pubitemid 46340378)
11. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-79. doi:10.1016/j.advenzreg. 2006.01.004.
12. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643-55. doi:10.1093/jnci/dji112. (Pubitemid 40812628)
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39. (Pubitemid 38637993)
14. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):57-61. doi:10.1371/journal.pmed.0020017.
15. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science. 2004;305(5687):1163-7. doi:10.1126/science.1101637. (Pubitemid 39100331)
16. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23(25):5900-9. doi:10.1200/JCO.2005.02.857.
17. Massarelli E, Varella-Garcia M, Tang XM, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2007;13(10):2890-6. doi:10.1158/1078-0432.CCR-06- 3043. (Pubitemid 46849563)
18. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 2004;10(20):6865-71. doi:10.1158/1078-0432.CCR-04-0174. (Pubitemid 39383035)
19. Galleges Ruiz MI, Floor K, Steinberg SM, Grünberg K, Thunnissen FB, Belien JA, et al. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer. 2009;100(1):145-52. doi:10.1038/sj.bjc.6604781.
20. Davis JM, Weinstein-Oppenheimer CR, Steelman LS, Navolanic PN, Hu W, Konopleva M, et al. Raf-1 and Bcl-2 induce distinct and common pathways which contribute to breast cancer drug resistance. Clin Cancer Res. 2003;9(3):1161-70. (Pubitemid 36323726)
21. Lee JT, Steelman LS, McCubrey JA. Modulation of Raf/MEK/ERK pathway in prostate cancer drug resistance. Int J Oncol. 2005;26(6):1637-44.
22. Lee JT, Steelman LS, McCubrey JA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004;64(22):8397-404. doi:10.1158/0008-5472.CAN-04-1612. (Pubitemid 39491779)
23. Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, et al. BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19(4):992-1000. (Pubitemid 32176273)
24. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-Cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46(6):685-93. doi:10.1111/j.1365-2559.2005. 02156.x. (Pubitemid 40834828)
25. Goss GD, Lorimer I, Tsao MS, O'Callaghan CJ, Ding K, Masters GA, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol ASCO Annual Meeting Proceedings. 2010;28(18suppl):LBA7005.
26. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-90. doi:10.1038/sj.onc.1210421. (Pubitemid 46763021)
27. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-310. doi:10.1038/sj.onc.1210422.
28. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23(11):2493- 501. doi:10.1200/JCO.2005.01.388. (Pubitemid 47050839)
29. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-rasmutation, and Akt phosphorylation. Clin Cancer Res. 2006;12(8):2538-44. doi:10.1158/1078-0432.CCR- 05-2845.
30. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchón C, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90(5):1047-52. doi:10.1038/sj.bjc.6601644. (Pubitemid 38495827)
31. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003;41(2):123-30. doi:10.1016/S0169-5002(03)00225-3. (Pubitemid 36842775)
32. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-64. doi:10.1038/sj.onc.1209085. (Pubitemid 41637985)
33. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 2006;24(2):306-14. doi:10.1200/JCO.2005.02.4133. (Pubitemid 46622059)
34. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986-97. (Pubitemid 32720961)
35. Tu ML, Wang HQ, Chen LJ, Lu JC, Jiang F, Liang JH, et al. Involvement of Akt1/protein kinase Balpha in tumor conditioned medium-induced endothelial cell migration and survival in vitro. J Cancer Res Clin Oncol. 2009;135(11):1543-50. doi:10.1007/s00432-009-0601-9.
36. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010;16(1):240-8. doi:10.1158/1078-0432.CCR-09-0986.
37. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51 (2):181-91. doi:10.1016/j.lungcan.2005.10.003.
38. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005;4(10):1369-72. (Pubitemid 41437124)
39. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 2001;94:774-82. (Pubitemid 33032823)
40. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol. 2001;28:56-66. (Pubitemid 33065111)
41. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res. 2003;9(6):2316-26. (Pubitemid 36687658)